Asthma
Conditions
Interventions
A:Tongchuanqing Granules(5 to 7 years: Take 1 bag (3G), 2 times a day. 8 to 10 years: take 1.5 bag (4.5g), 2 times a day. 11 to 14 years: take 2 bag (6g), 2 times a day)
B:placebo (5 to 7 years: Take 1 bag (3G), 2 times a day. 8 to 10 years: take 1.5 bag (4.5g), 2 times a day. 11 to 14 years: take 2 bag (6g), 2 times a day)
Sponsors
First Teaching Hospital of Tianjin University of Traditional Chinese Medicine
Eligibility
Sex/Gender
All
Age
5 Years to 14 Years
Inclusion criteria
Inclusion criteria: All must meet the following six criteria: 1. diagnosed with childrens Bronchial Asthma, chronic persistent period,Severity classification is 2nd or 3rd(mild persistent or moderate persistent); 2. Meeting deficiency asthma TCM syndrome; 3. Aged between 5 to 14 year-old; 4. Initial diagnosis or did not receive GINA standard treatment; 5. without use beta 2 agonists, glucocorticoids, oral beta 2 agonists, or leukotriene receptor antagonists in 2 weeks; not use systemic corticosteroids and immunomodulators in 4 weeks; 6. Fully informed, voluntary consent, and signed the ICF by legal guardians.
Exclusion criteria
Exclusion criteria: With one of the following items should not be included in this study 1. The patients have the other diseases that also cause breathlessness or dyspnea; 2. Complicated with serious life-threatening diseases, such as heart and brain blood vessels, liver, kidney and hematopoietic system disease ,or Wasting diseases,such as malignancies,tuberculosis and so on; 3. Can not use the test Syndrome condition explanation serum creatinine (Cr), blood urea nitrogen (BUN) and glutamic-pyruvic transaminase (ALT) increased; 4. Allergic to the drug used in this study; 5. Children can not cooperate or are participating in clinical trials of other drugs; 6. Children are too young to use peak flow meter; 7. According to the doctor's judgment, other diseases may reduce the including possibility or complicate including.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| PEF measured values(every morningt) and PEF mutation rate per week; | — |
Secondary
| Measure | Time frame |
|---|---|
| Forced expiratory volume in one second %predicted;The frequency and values of Daytime symptoms & Nocturnal Symptoms;Short-acting ?2 –agonist use; | — |
Countries
China
Contacts
Public ContactSiyuan Hu
Outcome results
None listed